In the treatment of KRAS mutant cancers, the key to exploiting synthetic lethality is to find stable mechanisms of synthetic lethal gene interactions; CRISPR/Cas technology has advanced the study of KRAS synthetic lethal interactions, partly due to the advantage of low false positive rates compared to other genetic approaches [75,76]. Here, KRAS is linked to cancer.